FDA/CDC

FDA approves betrixaban for VTE prophylaxis


 

Betrixaban, a factor Xa inhibitor, has been approved for the prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized with an acute illness, according to an announcement from the Food and Drug Administration.

Approval was based on results from a randomized, double-blind clinical trial in which over 7,000 hospitalized patients at risk for VTE received either extended-duration betrixaban (35-42 days) or short duration enoxaparin (6-14 days), a low molecular weight heparin administered subcutaneously. The rate of deep vein thrombosis, nonfatal pulmonary embolism, or VTE-related death was 4.4% among patients receiving betrixaban and 6% among patients receiving enoxaparin (relative risk, 0.75; 95% confidence interval: 0.61, 0.91).

FDA icon Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License
A total of 54% of patients receiving betrixaban had at least one adverse event, compared with 52% of patients receiving enoxaparin. The incidence of serious adverse events was also similar for both groups at 18% among betrixaban-treated patients and 17% among enoxaparin-treated patients. The most common adverse events were related to bleeding (2.4% for betrixaban and 1.2% for enoxaparin), which was also the most common reason for treatment discontinuation in both groups.

The recommended dosage for betrixaban is 80 mg per day for 35-42 days at the same time every day with food, after a dose of 160 mg on the first day of treatment.

Betrixaban will be marketed as Bevyxxa by Portola.

Find the full FDA announcement and prescribing information on the FDA website.

Recommended Reading

Principles learned from a successful improvement program can increase compliance and reduce hospital acquired VTEs (HA-VTEs) across multiple institutions
The Hospitalist
Dabigatran crushes warfarin for AF ablation
The Hospitalist
Preoperative VTEs occurred in 10% of cancer patients
The Hospitalist
New-onset AF boosts bad HFrEF outcomes
The Hospitalist
Guideline for reversal of antithrombotics in intracranial hemorrhage
The Hospitalist
Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis
The Hospitalist
Principles learned from a successful improvement program can increase compliance and reduce hospital acquired VTEs (HA-VTEs) across multiple institutions
The Hospitalist
Consider switch to clopidogrel for DAPT early post ACS
The Hospitalist
Infections up the risk for pregnancy-associated stroke in preeclampsia
The Hospitalist
Low-dose aspirin bests dual-antiplatelet therapy in TAVR
The Hospitalist
   Comments ()